|
|
Previous Article | Table of Contents | Next Article 
Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells
O Rosnet, C Schiff, MJ Pebusque, S Marchetto, C Tonnelle, Y Toiron, F Birg and D Birnbaum
Centre d'Immunologie de Marseille-Luminy, France.
The human FLT3 cDNA was cloned from a pre-B cell line and characterized.
The deduced amino acid sequence shows that FLT3 codes for a receptor-type
tyrosine kinase of 993 residues, presenting a strong similarity with the
corresponding mouse FLT3/FLK2 protein as well as with the receptors for
colony-stimulating factor 1 (CSF1R/FMS) and steel locus factor (SLFR/KIT).
An analysis of the expression of the gene using amplification of reverse
transcribed FLT3 mRNA by polymerase chain reaction shows that FLT3 is
expressed in various lymphohematopoietic cells and tissues, including a
series of immature cell lines and leukemias of lymphocytic origin.
Volume 82,
Issue 4,
pp. 1110-1119,
08/15/1993
Copyright © 1993 by The American Society of Hematology

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Li, O. Piloto, H. B. Nguyen, K. Greenberg, K. Takamiya, F. Racke, D. Huso, and D. Small
Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model
Blood,
April 1, 2008;
111(7):
3849 - 3858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C.H. de Vries, R. W. Stam, P. Schneider, C. M. Niemeyer, E. R. van Wering, O. A. Haas, C. P. Kratz, M. L. den Boer, R. Pieters, and M. M. van den Heuvel-Eibrink
Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia
Haematologica,
November 1, 2007;
92(11):
1557 - 1560.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Furuichi, K. Goi, T. Inukai, H. Sato, A. Nemoto, K. Takahashi, K. Akahane, K. Hirose, H. Honna, I. Kuroda, et al.
Fms-like Tyrosine Kinase 3 Ligand Stimulation Induces MLL-Rearranged Leukemia Cells into Quiescence Resistant to Antileukemic Agents
Cancer Res.,
October 15, 2007;
67(20):
9852 - 9861.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kiyoi, Y. Shiotsu, K. Ozeki, S. Yamaji, H. Kosugi, H. Umehara, M. Shimizu, H. Arai, K. Ishii, S. Akinaga, et al.
A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations
Clin. Cancer Res.,
August 1, 2007;
13(15):
4575 - 4582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Tarn, Y. V. Skorobogatko, T. Taguchi, B. Eisenberg, M. von Mehren, and A. K. Godwin
Therapeutic Effect of Imatinib in Gastrointestinal Stromal Tumors: AKT Signaling Dependent and Independent Mechanisms.
Cancer Res.,
May 15, 2006;
66(10):
5477 - 5486.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. W. Parcells, A. K. Ikeda, T. Simms-Waldrip, T. B. Moore, and K. M. Sakamoto
FMS-Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia
Stem Cells,
May 1, 2006;
24(5):
1174 - 1184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Tarn, E. Merkel, A. A. Canutescu, W. Shen, Y. Skorobogatko, M. J. Heslin, B. Eisenberg, R. Birbe, A. Patchefsky, R. Dunbrack, et al.
Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling
Clin. Cancer Res.,
May 15, 2005;
11(10):
3668 - 3677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Fukuda, H. E. Broxmeyer, and L. M. Pelus
Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1{alpha}(CXCL12)/CXCR4 axis
Blood,
April 15, 2005;
105(8):
3117 - 3126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Dewar, A. C. Cambareri, A. C. W. Zannettino, B. L. Miller, K. V. Doherty, T. P. Hughes, and A. B. Lyons
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Blood,
April 15, 2005;
105(8):
3127 - 3132.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Fry, M. Sinha, M. Milliron, Y.-W. Chu, V. Kapoor, R. E. Gress, E. Thomas, and C. L. Mackall
Flt3 ligand enhances thymic-dependent and thymic-independent immune reconstitution
Blood,
November 1, 2004;
104(9):
2794 - 2800.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Li, H. Li, M.-N. Wang, D. Lu, R. Bassi, Y. Wu, H. Zhang, P. Balderes, D. L. Ludwig, B. Pytowski, et al.
Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody
Blood,
August 15, 2004;
104(4):
1137 - 1144.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Mol, D. R. Dougan, T. R. Schneider, R. J. Skene, M. L. Kraus, D. N. Scheibe, G. P. Snell, H. Zou, B.-C. Sang, and K. P. Wilson
Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase
J. Biol. Chem.,
July 23, 2004;
279(30):
31655 - 31663.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-J. Lu, F. Li, L. Vida, and G. R. Honig
CD34+CD38- hematopoietic precursors derived from human embryonic stem cells exhibit an embryonic gene expression pattern
Blood,
June 1, 2004;
103(11):
4134 - 4141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ozeki, H. Kiyoi, Y. Hirose, M. Iwai, M. Ninomiya, Y. Kodera, S. Miyawaki, K. Kuriyama, C. Shimazaki, H. Akiyama, et al.
Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia
Blood,
March 1, 2004;
103(5):
1901 - 1908.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-Y. Shih, C.-F. Huang, J.-H. Wu, P.-N. Wang, T.-L. Lin, P. Dunn, M.-C. Chou, M.-C. Kuo, and C.-C. Tang
Heterogeneous Patterns of FLT3 Asp835 Mutations in Relapsed de Novo Acute Myeloid Leukemia: A Comparative Analysis of 120 Paired Diagnostic and Relapse Bone Marrow Samples
Clin. Cancer Res.,
February 15, 2004;
10(4):
1326 - 1332.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Minami, K. Yamamoto, H. Kiyoi, R. Ueda, H. Saito, and T. Naoe
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia
Blood,
October 15, 2003;
102(8):
2969 - 2975.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Murata, H. Kumagai, T. Kawashima, K. Tamitsu, M. Irie, H. Nakajima, S. Suzu, M. Shibuya, S. Kamihira, T. Nosaka, et al.
Selective Cytotoxic Mechanism of GTP-14564, a Novel Tyrosine Kinase Inhibitor in Leukemia Cells Expressing a Constitutively Active Fms-like Tyrosine Kinase 3 (FLT3)
J. Biol. Chem.,
August 29, 2003;
278(35):
32892 - 32898.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Mol, K. B. Lim, V. Sridhar, H. Zou, E. Y. T. Chien, B.-C. Sang, J. Nowakowski, D. B. Kassel, C. N. Cronin, and D. E. McRee
Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation
J. Biol. Chem.,
August 22, 2003;
278(34):
31461 - 31464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Grundler, C. Thiede, C. Miething, C. Steudel, C. Peschel, and J. Duyster
Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor
Blood,
July 15, 2003;
102(2):
646 - 651.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. W. H. Yee, A. M. O'Farrell, B. D. Smolich, J. M. Cherrington, G. McMahon, C. L. Wait, L. S. McGreevey, D. J. Griffith, and M. C. Heinrich
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase
Blood,
September 26, 2002;
100(8):
2941 - 2949.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L.-Y. Shih, C.-F. Huang, J.-H. Wu, T.-L. Lin, P. Dunn, P.-N. Wang, M.-C. Kuo, C.-L. Lai, and H.-C. Hsu
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
Blood,
September 18, 2002;
100(7):
2387 - 2392.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. O. Claudio, E. Masih-Khan, H. Tang, J. Goncalves, M. Voralia, Z. H. Li, V. Nadeem, E. Cukerman, O. Francisco-Pabalan, C. C. Liew, et al.
A molecular compendium of genes expressed in multiple myeloma
Blood,
August 28, 2002;
100(6):
2175 - 2186.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Gilliland and J. D. Griffin
The roles of FLT3 in hematopoiesis and leukemia
Blood,
August 13, 2002;
100(5):
1532 - 1542.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Thiede, C. Steudel, B. Mohr, M. Schaich, U. Schakel, U. Platzbecker, M. Wermke, M. Bornhauser, M. Ritter, A. Neubauer, et al.
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Blood,
May 29, 2002;
99(12):
4326 - 4335.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Mwangi, W. C. Brown, and G. H. Palmer
Identification of Fetal Liver Tyrosine Kinase 3 (Flt3) Ligand Domain Required for Receptor Binding and Function Using Naturally Occurring Ligand Isoforms
J. Immunol.,
December 15, 2000;
165(12):
6966 - 6974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Morelli, M. A. Antonysamy, T. Takayama, H. Hackstein, Z. Chen, S. Qian, N. B. Zurowski, and A. W. Thomson
Microchimerism, Donor Dendritic Cells, and Alloimmune Reactivity in Recipients of Flt3 Ligand-Mobilized Hemopoietic Cells: Modulation by Tacrolimus
J. Immunol.,
July 1, 2000;
165(1):
226 - 237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-C. Shih, M. C.-T. Hu, J. Hu, Y. Weng, P. J. Yazaki, J. Medeiros, and S. J. Forman
A secreted and LIF-mediated stromal cell-derived activity that promotes ex vivo expansion of human hematopoietic stem cells
Blood,
March 15, 2000;
95(6):
1957 - 1966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. J. Borge, J. Adolfsson, and A. M. I.-L. M. a. S. E.W. Jacobsen
Lymphoid-Restricted Development From Multipotent Candidate Murine Stem Cells: Distinct and Complimentary Functions of the c-kit and flt3-Ligands
Blood,
December 1, 1999;
94(11):
3781 - 3790.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Wolf and L. R. Rohrschneider
Fiz1, a Novel Zinc Finger Protein Interacting with the Receptor Tyrosine Kinase Flt3
J. Biol. Chem.,
July 23, 1999;
274(30):
21478 - 21484.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Kiyoi, T. Naoe, Y. Nakano, S. Yokota, S. Minami, S. Miyawaki, N. Asou, K. Kuriyama, I. Jinnai, C. Shimazaki, et al.
Prognostic Implication of FLT3 and N-RAS Gene Mutations in Acute Myeloid Leukemia
Blood,
May 1, 1999;
93(9):
3074 - 3080.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Yu, T. A. Fehniger, P. Fuchshuber, K. S. Thiel, E. Vivier, W. E. Carson, and M. A. Caligiuri
Flt3 Ligand Promotes the Generation of a Distinct CD34+ Human Natural Killer Cell Progenitor That Responds to Interleukin-15
Blood,
November 15, 1998;
92(10):
3647 - 3657.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Neipp, T. Zorina, M. A. Domenick, B. G. Exner, and S. T. Ildstad
Effect of FLT3 Ligand and Granulocyte Colony-Stimulating Factor on Expansion and Mobilization of Facilitating Cells and Hematopoietic Stem Cells in Mice: Kinetics and Repopulating Potential
Blood,
November 1, 1998;
92(9):
3177 - 3188.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. De Vivo, X. Cui, J. Domen, and M. L. Cleary
Growth stimulation of primary B cell precursors by the anti-phosphatase Sbf1
PNAS,
August 4, 1998;
95(16):
9471 - 9476.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. J. Graddis, K. Brasel, D. Friend, S. Srinivasan, S. Wee, S. D. Lyman, C. J. March, and J. T. McGrew
Structure-Function Analysis of FLT3 Ligand-FLT3 Receptor Interactions Using a Rapid Functional Screen
J. Biol. Chem.,
July 10, 1998;
273(28):
17626 - 17633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ikeda, K. Sasaki, K. Ikeda, G. Yamaoka, K. Kawanishi, Y. Kawachi, T. Uchida, J. Takahara, and S. Irino
A New Cytokine-Dependent Monoblastic Cell Line With t(9;11)(p22;q23) Differentiates to Macrophages With Macrophage Colony-Stimulating Factor (M-CSF) and to Osteoclast-Like Cells With M-CSF and Interleukin-4
Blood,
June 15, 1998;
91(12):
4543 - 4553.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. S. Gotze, M. Ramirez, K. Tabor, D. Small, W. Matthews, and C. I. Civin
Flt3high and Flt3low CD34+ Progenitor Cells Isolated From Human Bone Marrow Are Functionally Distinct
Blood,
March 15, 1998;
91(6):
1947 - 1958.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. D. Lyman and S. E. W. Jacobsen
c-kit Ligand and Flt3 Ligand: Stem/Progenitor Cell Factors With Overlapping Yet Distinct Activities
Blood,
February 15, 1998;
91(4):
1101 - 1134.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N Fortunel, P Batard, A Hatzfeld, M. Monier, B Panterne, J Lebkowski, and J Hatzfeld
High proliferative potential-quiescent cells: a working model to study primitive quiescent hematopoietic cells
J. Cell Sci.,
January 7, 1998;
111(13):
1867 - 1875.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Ebihara, K. Tsuji, S. D. Lyman, X. Sui, M. Yoshida, K. Muraoka, K. Yamada, R. Tanaka, and T. Nakahata
Synergistic Action of Flt3 and gp130 Signalings in Human Hematopoiesis
Blood,
December 1, 1997;
90(11):
4363 - 4368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Dooley, M. Xiao, B. K. Oppenlander, J. M. Plunkett, and S. D. Lyman
Flt3 Ligand Enhances the Yield of Primitive Cells After Ex Vivo Cultivation of CD34+ CD38dim Cells and CD34+ CD38dim CD33dim HLA-DR+ Cells
Blood,
November 15, 1997;
90(10):
3903 - 3913.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. N. Haylock, M. J. Horsfall, T. L. Dowse, H. S. Ramshaw, S. Niutta, S. Protopsaltis, L. Peng, C. Burrell, I. Rappold, H.-J. Buhring, et al.
Increased Recruitment of Hematopoietic Progenitor Cells Underlies the Ex Vivo Expansion Potential of FLT3 Ligand
Blood,
September 15, 1997;
90(6):
2260 - 2272.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Papayannopoulou, B. Nakamoto, R. G. Andrews, S. D. Lyman, and M. Y. Lee
In Vivo Effects of Flt3/Flk2 Ligand on Mobilization of Hematopoietic Progenitors in Primates and Potent Synergistic Enhancement With Granulocyte Colony-Stimulating Factor
Blood,
July 15, 1997;
90(2):
620 - 629.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|